RacecadotrilCAS# 81110-73-8 |
- Laminin (925-933)
Catalog No.:BCC1015
CAS No.:110590-60-8
- Epidermal Growth Factor Receptor Peptide (985-996)
Catalog No.:BCC1014
CAS No.:96249-43-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 81110-73-8 | SDF | Download SDF |
| PubChem ID | 107751 | Appearance | Powder |
| Formula | C21H23NO4S | M.Wt | 385.48 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Acetorphan | ||
| Solubility | DMSO : ≥ 100 mg/mL (259.42 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | benzyl 2-[[2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]acetate | ||
| SMILES | CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC2=CC=CC=C2 | ||
| Standard InChIKey | ODUOJXZPIYUATO-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H23NO4S/c1-16(23)27-15-19(12-17-8-4-2-5-9-17)21(25)22-13-20(24)26-14-18-10-6-3-7-11-18/h2-11,19H,12-15H2,1H3,(H,22,25) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Racecadotril (acetorphan), a potent enkephalinase inhibitor (IC50= 4.5 uM), protects endogenous enkephalins from degradation.
IC50 value: 4.5 uM
Target: Enkephalinase
Racecadotril is a peripherally acting enkephalinase inhibitor with an IC50 of 4.5 uM. Unlike other medications used to treat diarrhea, which reduce intestinal motility, Racecadotril has an antisecretory effect-it reduces the secretion of water and electrolytes into the intestine. A small randomized controlled trial found Racecadotril to significantly reduce the duration and volume of watery diarrhea in children when given as an adjunct to oral rehydration therapy. References: | |||||
Racecadotril Dilution Calculator
Racecadotril Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5942 mL | 12.9708 mL | 25.9417 mL | 51.8834 mL | 64.8542 mL |
| 5 mM | 0.5188 mL | 2.5942 mL | 5.1883 mL | 10.3767 mL | 12.9708 mL |
| 10 mM | 0.2594 mL | 1.2971 mL | 2.5942 mL | 5.1883 mL | 6.4854 mL |
| 50 mM | 0.0519 mL | 0.2594 mL | 0.5188 mL | 1.0377 mL | 1.2971 mL |
| 100 mM | 0.0259 mL | 0.1297 mL | 0.2594 mL | 0.5188 mL | 0.6485 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Racecadotril (acetorphan), a potent enkephalinase inhibitor (IC50= 4.5 uM), protects endogenous enkephalins from degradation.
- Clarithromycin
Catalog No.:BCC9219
CAS No.:81103-11-9
- Cisapride
Catalog No.:BCC4207
CAS No.:81098-60-4
- Pravastatin
Catalog No.:BCC4141
CAS No.:81093-37-0
- Kauniolide
Catalog No.:BCC5313
CAS No.:81066-45-7
- EUK 134
Catalog No.:BCC4317
CAS No.:81065-76-1
- Methyl 4-prenyloxycinnamate
Catalog No.:BCN7520
CAS No.:81053-49-8
- 4-Hydroxy-4-(methoxycarbonylmethyl)cyclohexanone
Catalog No.:BCN1346
CAS No.:81053-14-7
- Rhodamine B
Catalog No.:BCN7215
CAS No.:81-88-9
- Warfarin
Catalog No.:BCC5221
CAS No.:81-81-2
- Purpurin
Catalog No.:BCN3477
CAS No.:81-54-9
- Sennoside A
Catalog No.:BCN1002
CAS No.:81-27-6
- Cholic acid
Catalog No.:BCN1286
CAS No.:81-25-4
- N-Nonyldeoxynojirimycin
Catalog No.:BCC7752
CAS No.:81117-35-3
- (Z)-Lachnophyllum lactone
Catalog No.:BCN4746
CAS No.:81122-95-4
- Cilastatin sodium
Catalog No.:BCC7457
CAS No.:81129-83-1
- Pravastatin sodium
Catalog No.:BCC2321
CAS No.:81131-70-6
- RR-src
Catalog No.:BCC6956
CAS No.:81156-93-6
- Imiloxan hydrochloride
Catalog No.:BCC6875
CAS No.:81167-22-8
- Apatinib
Catalog No.:BCC5099
CAS No.:811803-05-1
- Boc-D-Tyr(2-Br-Z)-OH
Catalog No.:BCC3464
CAS No.:81189-61-9
- Panaxynol
Catalog No.:BCN3833
CAS No.:81203-57-8
- L-741,626
Catalog No.:BCC6886
CAS No.:81226-60-0
- 15-Deoxoeucosterol
Catalog No.:BCN4348
CAS No.:81241-53-4
- ent-9-Hydroxy-15-oxo-16-kauren-19-oic acid beta-D-glucopyranosyl ester
Catalog No.:BCN1345
CAS No.:81263-96-9
Racecadotril for the treatment of severe acute watery diarrhoea in children admitted to a tertiary hospital in Kenya.[Pubmed:28123772]
BMJ Open Gastroenterol. 2017 Jan 3;4(1):e000124.
BACKGROUND: Diarrhoea is the second most common cause of death in children under 5 years of age in Kenya. It is usually treated with oral rehydration, zinc and continued feeding. Racecadotril has been in use for over 2 decades; however, there is a paucity of data regarding its efficacy from Africa. OBJECTIVES: The objectives of this study were: to compare the number of stools in the first 48 hours in children with severe gastroenteritis requiring admission and treated with either Racecadotril or placebo, to study the impact of Racecadotril on duration of inpatient stay as well as duration of diarrhoea and to describe the side effect profile of Racecadotril. METHODS: This was a randomised, double-blinded, placebo-controlled trial. It enrolled children between the age of 3 and 60 months who were admitted with severe acute gastroenteritis. They received either Racecadotril or placebo in addition to oral rehydration solution (ORS) and zinc and were followed up daily. RESULTS: 120 children were enrolled into the study. There were no differences in the demographics or outcomes between the 2 groups. Stools at 48 hours: median (IQR) of 5 (3-7) and 5 (2.5-7.5), respectively; p=0.63. The duration of inpatient stay: median (IQR): 4 days (1.5-6.5) and 4.5 (1.8-6.3); p=0.71. The duration of illness: 3 days (2-4) and 2 days (1-3); p=0.77. The relative risk of a severe adverse event was 3-fold higher in the drug group but was not statistically significant (95% CI 0.63 to 14.7); p=0.16. CONCLUSIONS: Racecadotril has no impact on the number of stools at 48 hours, the duration of hospital stay or the duration of diarrhoea in children admitted with severe gastroenteritis and managed with ORS and zinc. TRIAL REGISTRATION NUMBER: PACTR201403000694398; Pre-results.
A Comprehensive Comparison of the Efficacy and Tolerability of Racecadotril with Other Treatments of Acute Diarrhea in Adults.[Pubmed:27790616]
Front Med (Lausanne). 2016 Oct 14;3:44.
Racecadotril is a guideline-recommended treatment to alleviate symptoms of acute diarrhea. A systematic review of randomized studies was performed comparing efficacy and safety of treatment with Racecadotril to that with placebo or active treatments in adults. In five double-blind studies, Racecadotril and placebo had comparable tolerability, but Racecadotril was more effective. This was consistent across multiple efficacy parameters including duration of diarrhea, number of diarrheic stools, abdominal pain, and meteorism; it was also consistent across countries in Africa, Asia, and Europe. In six randomized studies in outpatients comparing Racecadotril to loperamide, resolution of symptoms occurred with similar speed and efficacy; however, Racecadotril treatment was associated with less rebound constipation and less abdominal discomfort. The seventh comparative study performed in geriatric nursing home residents reported a superior efficacy of Racecadotril. In direct comparison with Saccharomyces boulardii treatment, Racecadotril exhibited similar tolerability but was more efficacious. One study compared Racecadotril to octreotide in patients with acute diarrhea requiring hospitalization, rehydration, and antibiotic treatment; in this cohort, octreotide was more efficacious than Racecadotril. In conclusion, in adults with acute diarrhea, Racecadotril is more efficacious than placebo or S. boulardii, similarly efficacious as loperamide and, in patients with moderate to severe disease as add-on to antibiotics, less than octreotide. The tolerability of Racecadotril is similar to that of placebo or S. boulardii and better than that of loperamide, particularly with regard to risk of rebound constipation. Taken together, these data demonstrate that Racecadotril is a suitable treatment to alleviate symptoms of acute diarrhea in adults.
